Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Stephen I. Pelton, MD
In the last two pre-pandemic flu seasons, approximately half of hospitalizations from influenza in the US were in adults 65 and older.1,2 A recent real-world study evaluated the relative effectiveness of adjuvanted influenza vaccine versus high-dose vaccine in preventing test-confirmed influenza hospitalizations in this age group across three flu seasons between 2017 and 2020.3 Dr. Charles Turck sits down with Dr. Stephen Pelton, an author on this study, to explore the findings and their implications for influenza vaccination strategies in older adults. Dr. Pelton is a Professor of Pediatrics at the Boston University Chobanian and Avedisian School of Medicine.
References:
- Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA.
- Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023;11:1525.
- McGovern I, Chastek B, Bancroft T, et al. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons. Int J Infect Dis. …